This study is looking at whether using a CardioMEMS device can help reduce hospital stays for people with heart failure who have a HeartMate III Left Ventricular Assist Device (LVAD) implanted. The CardioMEMS device is a small sensor placed in your pulmonary artery (a blood vessel in your lungs) that measures pressures daily from home. Researchers want to see if monitoring these pressures helps keep patients out of the hospital compared to standard care. You may be able to join if you are between 21 and 85 years old, have a working HeartMate III LVAD, and are stable enough to go home. The main goal is to see if fewer heart failure-related hospitalizations occur over about one year.

Study design

This is a single-center pilot study that will randomly assign 40 participants to either receive the CardioMEMS device or standard care. It is an open-label study, meaning both you and your doctors will know which treatment you are receiving.

What's involved

If you participate, you would have the CardioMEMS device implanted during a right heart catheterization procedure. After implantation, you would take daily pulmonary artery pressure measurements using a home monitoring system.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, heart failure-related hospitalizations, will be measured through study completion, which is an average of one year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.